Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

268
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
268
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

941
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
941
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

454
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
454

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The collection of speech data for the assessment of cognition remotely: Balancing ethical and practical challenges.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Midlife dementia risk and later dementia-related fear and avoidance: evidence from a prospective cohort study.

Aging & mental health·2026
Same author

Hair cortisol-to-cortisone ratio and dental caries in adolescents: a cross-sectional analysis of glucocorticoid imbalance and caries prevalence.

BMC oral health·2026
Same author

Development and validation of a dementia risk prediction model for low- and middle-income countries: the 10/66 study.

American journal of epidemiology·2026
Same author

Genetic risk of Alzheimer's disease is associated with loss of brain network segregation in midlife.

Communications biology·2026
Same author

A Bayesian Location-Scale Joint Model for Time-To-Event and Multivariate Longitudinal Data With Association Based on Within-Individual Variability.

Statistics in medicine·2026
Same journal

Deep learning model to predict COPD hospital admissions based on meteorological data: a medical meteorological forecast.

Frontiers in big data·2026
Same journal

Where diverse populations gather: transit accessibility and the spatial structure of social mixing.

Frontiers in big data·2026
Same journal

Inner layer security reinforcement for instant payment systems: a dual layer encryption-steganography evaluation in Brunei's digital payment context.

Frontiers in big data·2026
Same journal

Measuring the impact of virtualization and containerization on the environment when using GPUs for processing the AI models.

Frontiers in big data·2026
Same journal

Using artificial intelligence to improve governance and public services in Africa.

Frontiers in big data·2026
Same journal

Case count metric for comparative analysis of entity resolution results.

Frontiers in big data·2026
See all related articles

Related Experiment Video

Updated: Nov 2, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K

Developing an Explainable Machine Learning-Based Personalised Dementia Risk Prediction Model: A Transfer Learning

Samuel O Danso1, Zhanhang Zeng2, Graciela Muniz-Terrera1

  • 1Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh Medical School, Edinburgh, United Kingdom.

Frontiers in Big Data
|June 14, 2021
PubMed
Summary
This summary is machine-generated.

We developed an explainable AI model for early Alzheimer's disease (AD) risk prediction. This model uses transfer learning to improve accuracy in predicting dementia, offering valuable clinical insights for early detection.

Keywords:
Alzheimer'searly detectionensemble-based learningexplainable AI modelpersonalised dementia riskrisk factors

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.3K

Related Experiment Videos

Last Updated: Nov 2, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.3K

Area of Science:

  • Computational neuroscience and artificial intelligence in healthcare.
  • Biomarker discovery and predictive modeling for neurodegenerative diseases.

Background:

  • Alzheimer's disease (AD) onset precedes dementia by decades, necessitating early detection methods.
  • Current machine learning models for AD risk prediction face limitations in generalizability and clinical utility.
  • Existing models often suffer from data source over-reliance and lack of interpretability.

Purpose of the Study:

  • To develop explainable, personalized risk prediction models for dementia using a transfer-learning framework.
  • To enhance the generalizability and clinical applicability of predictive models for early Alzheimer's disease detection.

Main Methods:

  • Employed a transfer-learning paradigm with ensemble learning algorithms.
  • Trained 'source models' on a large public dataset (n=84,856) and refined them with a smaller, younger dataset (n=473) to create 'target models'.
  • Utilized the SHapely Additive exPlanation (SHAP) algorithm for visualizing prediction drivers.

Main Results:

  • The best source model achieved 87% geometric accuracy, 99% specificity, and 76% sensitivity.
  • The target model demonstrated significant performance improvements over a baseline model, including a 16.9% increase in geometric accuracy and 19.1% in sensitivity.
  • The approach showed a transfer learning efficacy rate of 20.6% and provided interpretable risk factor visualizations.

Conclusions:

  • The proposed framework effectively enhances dementia risk prediction through transfer learning and ensemble methods.
  • Explainable AI (SHAP) provides crucial insights into risk factors, increasing clinical utility for early AD detection.
  • This approach offers a robust and clinically relevant tool for identifying individuals at risk of developing dementia.